MEI Pharma Executive Compensation Details Revealed
Ticker: LITS · Form: DEF 14A · Filed: Dec 20, 2024 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Mei Pharma, INC. (LITS) |
| Form Type | DEF 14A |
| Filed Date | Dec 20, 2024 |
| Risk Level | medium |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, governance
TL;DR
MEI Pharma dropped its proxy statement detailing exec pay for FY24. Check out those stock options!
AI Summary
MEI Pharma, Inc. filed a DEF 14A on December 20, 2024, detailing executive compensation for the fiscal year ending June 30, 2024. The filing includes information on stock and option awards granted to executives like David Urso and Daniel Gold, with specific values reported for the covered years, including changes from prior years.
Why It Matters
This filing provides transparency into how MEI Pharma compensates its top executives, which can influence investor decisions and perceptions of company management.
Risk Assessment
Risk Level: medium — DEF 14A filings, while routine, can reveal information about executive compensation and corporate governance that may impact investor confidence and stock price.
Key Numbers
- 20241220 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 0630 — Fiscal Year End (Indicates the end of the reporting period for financial information.)
Key Players & Entities
- MEI Pharma, Inc. (company) — Filer of the DEF 14A
- David Urso (person) — Executive mentioned in relation to compensation awards
- Daniel Gold (person) — Executive mentioned in relation to compensation awards
- 20241220 (date) — Filing date of the DEF 14A
- 0630 (date) — Fiscal year end date
FAQ
What is the primary purpose of this DEF 14A filing by MEI Pharma, Inc.?
The primary purpose is to provide detailed information regarding the company's executive compensation, director compensation, and other corporate governance matters, as required by SEC regulations.
Who are the key executives whose compensation details are likely included in this filing?
Key executives mentioned in relation to compensation awards include David Urso and Daniel Gold.
What specific types of compensation are detailed in this filing?
The filing details stock and option awards, including their fair value, and changes in these awards from prior years for outstanding unvested awards.
What is the fiscal year end for MEI Pharma, Inc. as stated in the filing?
MEI Pharma, Inc.'s fiscal year ends on June 30 (0630).
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted on December 20, 2024 (20241220).
Filing Stats: 4,756 words · 19 min read · ~16 pages · Grade level 10.6 · Accepted 2024-12-20 17:10:13
Filing Documents
- meip-20241220.htm (DEF 14A) — 1008KB
- img105009773_0.jpg (GRAPHIC) — 1KB
- img105009773_1.jpg (GRAPHIC) — 1KB
- img105009773_2.jpg (GRAPHIC) — 1KB
- img105009773_3.jpg (GRAPHIC) — 1KB
- img105009773_4.jpg (GRAPHIC) — 1KB
- img105009773_5.jpg (GRAPHIC) — 1KB
- img105009773_6.jpg (GRAPHIC) — 1KB
- img105009773_7.jpg (GRAPHIC) — 1KB
- img105009773_8.jpg (GRAPHIC) — 1KB
- img105009773_9.jpg (GRAPHIC) — 1KB
- img105009773_10.jpg (GRAPHIC) — 1KB
- img105009773_11.jpg (GRAPHIC) — 1KB
- img105009773_12.jpg (GRAPHIC) — 1KB
- img105009773_13.jpg (GRAPHIC) — 1KB
- img105009773_14.jpg (GRAPHIC) — 122KB
- img105009773_15.jpg (GRAPHIC) — 101KB
- img105009773_16.jpg (GRAPHIC) — 97KB
- img105009773_17.jpg (GRAPHIC) — 94KB
- img105009773_18.jpg (GRAPHIC) — 98KB
- 0000950170-24-139131.txt ( ) — 3479KB
- meip-20241220.xsd (EX-101.SCH) — 28KB
- meip-20241220_htm.xml (XML) — 486KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 17 Summary Compensation Table 17 Employment Agreements 17 Grants of Plan-Based Awards For Fiscal Year Ended June 30, 2023 19 Outstanding Equity Awards at Fiscal Year-End 20 Option Exercises and Stock Vested 21 Compensation of Directors 26 Indemnification Agreements 27
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF MEI PHARMA
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT OF MEI PHARMA 27 WHERE YOU CAN FIND MORE INFORMATION 29 OTHER MATTERS FOR STOCKHOLDERS 29 Stockholder Proposals 29 Communication with the MEI Pharma Board of Directors 29 Householding of Proxy Materials for MEI Pharma Stockholders 29 RATIFICATION OF APPOINTMENT OF Deloitte & Touche LLP (PROPOSAL NO. 3) 31 Background 31 Fees Paid to Independent Registered Public Accounting Firm 31 Pre-Approval Policies and Procedures 31 AUDIT COMMITTEE REPORT 32 i MEI PHARMA, INC. 9920 Pacific Heights Blvd., Suite 150 San Diego, CA 92121 THE ANNUAL MEETING OF M EI PHARMA STOCKHOLDERS To Be Held via Live Webcast on January 30, 2025, at 9:00 a.m. (Pacific Time) Important Notice Regarding the Availability of Proxy Materials for the Stockholders' Meeting To Be Held on January 30, 2025 This Proxy Statement and our annual report to security holders for the fiscal year ended June 30, 2024 are available at www.edocumentview.com/MEIP. Information Concerning Solicitation and Voting In this Proxy Statement, "MEI Pharma", "the Company", "we", "us", and "our" refer to MEI Pharma, Inc., unless the context otherwise provides. General We are furnishing this Proxy Statement to holders of our common stock in connection with the solicitation of proxies by our board of directors (the Board) for use at our annual meeting of stockholders (the Annual Meeting) to be held on January 30, 2025 and at any adjournment or postponement thereof. Pursuant to rules adopted by the Securities and Exchange Commission (SEC), we are using the Internet as the primary means of furnishing proxy materials to our stockholders. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials (the Notice) to our stockholders. The Notice contains instructions on how to access the proxy materials and vote your shares of common stock over the Internet. The Notice also contains instructio